Phathom Pharmaceuticals, Inc. Capital Stock Change

Capital Stock Change of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital Stock Change growth rates and interactive chart.


Highlights and Quick Summary

  • Capital Stock Change for the quarter ending June 29, 2021 was $104 Thousand (a -74.76% decrease compared to previous quarter)
  • Year-over-year quarterly Capital Stock Change decreased by -99.95%
  • Annual Capital Stock Change for 2020 was $89.5 Million (a -53.28% decrease from previous year)
  • Annual Capital Stock Change for 2019 was $191 Million (a 9573500.0% increase from previous year)
  • Twelve month Capital Stock Change ending June 29, 2021 was $283 Million (a 0.5% increase compared to previous quarter)
Trailing Capital Stock Change for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20
$283 Million $281 Million $281 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital Stock Change of Phathom Pharmaceuticals, Inc.

Most recent Capital Stock Changeof PHAT including historical data for past 10 years.

Interactive Chart of Capital Stock Change of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Capital Stock Change for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.1 $0.41
2020 $89.46 $89.46
2019 $192.77 $-1.3 $191.47
2018 $0.0 $0.0

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.